Actinic Keratoses and Other Precursors of Keratinocytic Cutaneous Malignancies

[1]  R. G. Mackay.  Diseases of the Nose, Throat and Ear: A Handbook for Students and Practitioners , 1976 .

[2]  J. Callen,et al.  Bowen's and non-Bowen's squamous intraepidermal neoplasia of the skin. Relationship to internal malignancy. , 1980, Archives of dermatology.

[3]  R. Marks,et al.  Non‐melanotic skin cancer and solar keratoses in Victoria , 1983, The Medical journal of Australia.

[4]  G. Kao.  Carcinoma arising in Bowen's disease. , 1986, Archives of dermatology.

[5]  R. Kaplan.  Cancer complicating chronic ulcerative and scarifying mucocutaneous disorders. , 1987, Advances in dermatology.

[6]  D. Ransohoff,et al.  Is Bowen's disease a predictor for the development of internal malignancy? A methodological critique of the literature. , 1987, JAMA.

[7]  R. Marks,et al.  Skin cancer in a Queensland population. , 1988, Journal of the American Academy of Dermatology.

[8]  T. Hamilton,et al.  Topical tretinoin improves photoaged skin. A double-blind vehicle-controlled study. , 1988, JAMA.

[9]  S. Tajuri,et al.  Postburn scar carcinoma. , 1989, Burns : journal of the International Society for Burn Injuries.

[10]  N. Swanson,et al.  Squamous cell carcinoma of the skin (excluding lip and oral mucosa). , 1992, Journal of the American Academy of Dermatology.

[11]  J. McGrath,et al.  Epidermolysis bullosa complicated by squamous cell carcinoma: report of 10 cases , 1992, Journal of cutaneous pathology.

[12]  J. Tschen,et al.  PROLIFERATIVE ACTINIC KERATOSIS , 1994, International journal of dermatology.

[13]  N. Cox.  Actinic keratoses induced by a sunbed , 1994, BMJ.

[14]  R. Tarone,et al.  Frequent clones of p53-mutated keratinocytes in normal human skin. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. H. Kim,et al.  p53 mutations in solar keratoses. , 1996, Human pathology.

[16]  D. Alberts,et al.  Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  R. Stern,et al.  Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. , 1998, Archives of dermatology.

[18]  N. Conrad,et al.  Incipient intraepidermal cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratoses. , 1999, Seminars in cutaneous medicine and surgery.

[19]  J. Saurat,et al.  Topical Colchicine Therapy for Actinic Keratoses , 2000, Dermatology.

[20]  C. Cockerell,et al.  Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). , 2000, Journal of the American Academy of Dermatology.

[21]  E. Tschen,et al.  Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses , 2001, International journal of dermatology.

[22]  C. Ulrich,et al.  A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. , 2002, Archives of dermatology.

[23]  J. Jorizzo,et al.  Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. , 2002, Cutis.

[24]  Victor Siskind,et al.  Sun exposure and interaction with family history in risk of melanoma, Queensland, Australia , 2002, International journal of cancer.

[25]  G. Halliday,et al.  Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans , 2002, The British journal of dermatology.

[26]  Y. Poulin,et al.  Topical treatment of actinic keratoses with 3·0% diclofenac in 2·5% hyaluronan gel , 2002, The British journal of dermatology.

[27]  S. Salasche,et al.  Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial. , 2002, Journal of the American Academy of Dermatology.

[28]  C. Cockerell,et al.  Pathology and pathobiology of the actinic (solar) keratosis , 2003, The British journal of dermatology.

[29]  J. K. Walker,et al.  Is imiquimod effective and safe for actinic keratosis? , 2003, The Journal of family practice.

[30]  Clay J Cockerell,et al.  The actinic (solar) keratosis: a 21st-century perspective. , 2003, Archives of dermatology.

[31]  A. Ackerman.  Solar keratosis is squamous cell carcinoma. , 2003, Archives of dermatology.

[32]  Murad Alam,et al.  The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. , 2004, Clinics in dermatology.

[33]  S. Euvrard,et al.  Systemic and Topical Retinoids in the Management of Skin Cancer in Organ Transplant Recipients , 2004, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[34]  D. Murrell,et al.  A prospective study of the use of cryosurgery for the treatment of actinic keratoses , 2004, International journal of dermatology.

[35]  T. Saida,et al.  Early cancers of the skin: clinical, histopathological, and molecular characteristics , 2005, International Journal of Clinical Oncology.

[36]  M. Hussein.  Ultraviolet radiation and skin cancer: molecular mechanisms , 2005, Journal of cutaneous pathology.

[37]  C. Cockerell,et al.  New histopathological classification of actinic keratosis (incipient intraepidermal squamous cell carcinoma). , 2005, Journal of drugs in dermatology : JDD.

[38]  R. Moy,et al.  Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. , 2005, Archives of dermatology.

[39]  C. Mélot,et al.  Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies , 2005, Archives of Dermatological Research.

[40]  H. Terai,et al.  Cheilitis as a variation of Candida-associated lesions. , 2006, Oral diseases.

[41]  M. Thissen,et al.  Actinic keratosis: how to differentiate the good from the bad ones? , 2006, European journal of dermatology : EJD.

[42]  M. Quintanilla,et al.  Molecular biology of malignant melanoma and other cutaneous tumors , 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[43]  S. Derry,et al.  Imiquimod for actinic keratosis: systematic review and meta-analysis. , 2006, The Journal of investigative dermatology.

[44]  J. McGregor,et al.  Guidelines for the management of actinic keratoses , 2007, The British journal of dermatology.

[45]  A. Ehrlich,et al.  Actinic keratosis: an occupational and environmental disorder , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[46]  N. Kerrouche,et al.  Multicentre intraindividual randomized trial of topical methyl aminolaevulinate–photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities , 2008, The British journal of dermatology.

[47]  D. Rigel,et al.  Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. , 2008, Journal of drugs in dermatology : JDD.

[48]  M. Shaffelburg.  Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream. , 2009, Journal of drugs in dermatology : JDD.

[49]  S. Mickan,et al.  Effectiveness of 5‐fluorouracil treatment for actinic keratosis – a systematic review of randomized controlled trials , 2009, International journal of dermatology.

[50]  I. Bassukas,et al.  Combination of cryosurgery and topical imiquimod: does timing matter for successful immunocryosurgery? , 2009, Cryobiology.

[51]  G. Goldenberg,et al.  Viral-Associated Nonmelanoma Skin Cancers: A Review , 2009, The American Journal of dermatopathology.

[52]  E. Tschen,et al.  Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. , 2009, Journal of the American Academy of Dermatology.